Register
Login:
Share:
Email Facebook Twitter

#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects Watch Here

#AST: Board changes and new strategy for Ascent as Hutchinson looks at new projects
EXCLUSIVE: Petro Matad announce fully funded 4 well Mongolia campaign


Faron Pharma Share Chat (FARN)



Share Price: 53.00Bid: 51.00Ask: 55.00Change: 0.00 (0.00%)No Movement on Faron Pharma
Spread: 4.00Spread as %: 7.84%Open: 53.00High: 53.00Low: 53.00Yesterday’s Close: 53.00


Share Discussion for Faron Pharma


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

dyl79
Posts: 77
Opinion:No Opinion
Price:53.00
RE: NEWS
Today 12:54
My average is 80p which I’m ok with. Seeing it back above £1 by the spring/summer would do me to start off with!
 
Kev7722
Posts: 276
Opinion:No Opinion
Price:53.00
RE: NEWS
Today 10:20
Hi Scully - FWIW my average is about 10p higher than yours and I'm still pretty confident that I'll be in profit this year... as long as you're not holding out for the promised £50 a share then I have a feeling you'll probably be fine.
Scully12345
Posts: 6,650
Opinion:No Opinion
Price:53.00
RE: NEWS
Today 09:55
Investinvalue I have a fair amount of money in farn at average 65p. Are we going to make money soon?
Kev7722
Posts: 276
Opinion:No Opinion
Price:53.00
RE: NEWS
Today 09:29
Results of which trial will be sending this through the roof? Japan (due 'early 2019', not necessarily meaning Jan) are unlikely to have much impact in isolation, and the remaining findings from YODA (due 'Q1 2019', again not necessarily meaning Jan) will hopefully add enough weight to the steroid interference theory to cue up a new trial on ARDS patients...

The latter would be good news, and should have a positive impact on the SP, but any partner coming on board before the drug is fully proven and de-risked is going to push for much more favourable terms - so IMO we're either looking at additional fundraising or a worse deal than in the initial trial had been a success.

Still a lot of scope for recovery here, but I'm not paying much attention to people who say this will 50-bag or 100-bag this year... it wont.
dyl79
Posts: 77
Opinion:No Opinion
Price:53.00
be careful
Today 09:24
Be careful guys, only invest what you can loose. There are some sad stories on flybe of people loosing £10ns of thousands of pounds when the BOD sold the company without any type of shareholder consultation. Dodgy dealings at its best.

I believe in this share but I only have invested what I can afford to loose as well.
Investinvalue
Posts: 557
Opinion:Strong Buy
Price:53.00
NEWS
Today 09:05
Imminent! Due before end of months sending this through the roof. Strong Buy! Partners getting ready to make a huge offer on results of trial.

Who wants to make a fortune?
cj62
Posts: 193
Premium Chat Member
Opinion:No Opinion
Price:53.00
RE: Solace
Today 07:10
99 x what's it's worth now. Wow that would be a boom but Zen I do think you are getting a little excited with the forecast. Let's get to a pound first
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Solace
Tue 21:56
Only 31mil shares...most tightly held
OilMan1984
Posts: 165
Premium Chat Member
Opinion:No Opinion
Price:53.00
RE: Solace
Tue 20:42
Zen, what are you smoking this year!? £50 a share!!!!
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Solace
Tue 18:29
If I were the CEO, I would not want to be talking to the Partner for less than 500mil upfront and would want £2bil on Phase III success...subject to 2040 IP + share of sales.

£50 per share IMO
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Solace
Tue 18:25
The CEO talks about Partner discussion in 5th December 2018 Pro-Active - Faron Pharma confident Traumakine could be ‘very effective’ for ARDS subgroup...more news has gone on than that read the RNS's!

https://www.proactiveinvestors.co.uk/companies/stocktube/11455/faron-pharma-confident-traumakine-could-be-very-effective-for-ards-subgroup-11455.html

Group - 4.2% morality - outstanding result!
Precise Group - optimum for 1/3 third of patients
Data - European and US - very valuable and a small trial.
Partnering discussion - True and Clear path with interesting discussion
Intercultural property - very confident that the IP will be extended to 2040

All looking good to me at 17 mil Mcap.

Bring on the YODA, Bring on the Partner, Bring on the re-rate to many multiples of this price.....IMVHO.
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Solace
Tue 18:10
CW - I report and comment on the facts...those that have been released by formal RNS

You carry on as you are.

GL
cwebb07
Posts: 50
Opinion:No Opinion
Price:53.00
Solace
Tue 18:08
Everyone would like Farn to do well.

The facts are the SP is close to 50p.

I now understand that Zen has a huge paper loss and if the constant copy and pastes and references to Partners that can't be backed up give just a little Solace, then of course that is fine
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Zengah
Tue 17:48
And Just so you know - Jay_P

Don't you think you may be better concentrating on Anglo Afri O&g Share Price (AAOG)?

You seem to have changed your opinion to buy and sell in a day or so on AAOG...so the trust is not warranted,

In terms of FARN your last message posted 5th December 2018, you said -

'It works, it works, it works! Tell all ya friends, family and strangers on the street!

'But seriously, this is good news for those suffering from ARDS. A lot of the hard work has been done by Faron in identifying the sub group and hopefully now, pending approval from the necessary regulatory bodies, they can take this to market as quickly as possible.'

GL
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Zengah
Tue 17:46
Don't you think you may be better concentrating on Anglo Afri O&g Share Price (AAOG)?

You seem to have changed your opinion to buy and sell in a day or so on AAOG...so the trust is not warranted,

In terms of FARN your last message posted 5th December 2018, you said -

'It works, it works, it works! Tell all ya friends, family and strangers on the street!

'But seriously, this is good news for those suffering from ARDS. A lot of the hard work has been done by Faron in identifying the sub group and hopefully now, pending approval from the necessary regulatory bodies, they can take this to market as quickly as possible.'

GL
Jay_P
Posts: 142
Opinion:No Opinion
Price:53.00
Zengah
Tue 17:08
Finally filtered.
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: 10 posts
Tue 14:35
Kev, please respect others posts
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Let the games carry on
Tue 14:32
Here you go - FACTS!

https://www.investegate.co.uk/faron-pharma--oy--farn-/rns/patient-subgroup-identified-from-interest-trial/201812050700024471J/

''In patients with the C/T polymorphism who received Traumakine but not concurrent steroid treatment, mortality was only 4.2% (n=25).''

''This finding has also allowed us to build further intellectual property for Traumakine as this association has not been previously reported. This protection has been filed and, if approved, could extend beyond 2040."

I expect the Partner will love that...probably a request IMO.

GL Partner.
Kev7722
Posts: 276
Opinion:No Opinion
Price:53.00
RE: 10 posts
Tue 14:30
I'm trying to picture Markku Jalkanen's next Proactive interview, in which he ends every other sentence with a 'BOOM'...
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: 10 posts
Tue 14:28
CW, I have posted factual information so do not start saying after 10 posts I am clogging up this board.

You have not put anything constructive on here so you are not really worth responding too.

All the best though
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Let the games carry on
Tue 14:26
Then we have this -

Optimal subgroup of ARDS patients for Traumakine treatment identified by genetic testing showing substantial reduction in mortality among INTEREST trial patients

In patients with the C/T polymorphism who received Traumakine but not concurrent steroid treatment, mortality was only 4.2% (n=25).

Yep 4.2%....BOOM

4.2% mortality rate within the identified reseptor group.

1/3rd of the population with ARDS

Strap in for the ride - due on the YODA update and Partner entry.

I hope our Partner is doing well xx
cwebb07
Posts: 50
Opinion:No Opinion
Price:53.00
10 posts
Tue 14:22
....today already by Zen and the SP is down....the trend continues
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Let the games carry on
Tue 14:21
Now, 5th December produced the following -

Optimal subgroup of ARDS patients for Traumakine treatment identified by genetic testing showing substantial reduction in mortality among INTEREST trial patients

Well what about that?...

Then the 14th December 2018 we had this - First patient dosed in phase I/II MATINS study of Clevegen

Dr Markku Jalkanen, Chief Executive Officer of Faron, said: "We are delighted that Clevegen has advanced into the clinic. We have already seen promising pre-clinical and ex-vivo human data, and so this is a significant step in helping us to further understand the potential of this novel therapy. We are pleased to have achieved such rapid progress with our Clevegen programme so far and look forward to the opening of further trial sites and the expansion of the study in Europe and USA."

Then on the 19th December 2018 we had the best news - Traumakine update

Dr Markku Jalkanen, CEO of Faron, said: "We believe these results confirm that the drug product used in the INTEREST study was robust and effective. While analysis continues, we believe the mixed results seen were due to a higher than anticipated placebo response due to high pneumonia portion, interference of corticosteroids on IFN-beta bioactivity and, as recently announced, the impact of a subgroup of patients' single nucleotide polymorphism C/T mutation in their interferon alpha and beta receptor gene."
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Let the games carry on
Tue 14:16
Now, you say this 'is the best best RNS Farn has released for some time'?...im not sure myself how you compare that comment to other releases like -

3rd December 2018 - Faron receives regulatory approval to initiate clinical MATINS trial for precision cancer immunotherapy Clevegen

6th November 2018 - PDMR Dealings

22nd October 2018 - INTEREST trial update - Routine corticosteroid treatment correlates with increased mortality and decreased Traumakine efficacy.

Small window - yep!

Now...your disappointment may be apparent but don't get in front of yourself without adding to your post, the cold facts
Zengah
Posts: 887
Opinion:No Opinion
Price:53.00
RE: Let the games carry on
Tue 14:05
What I will say dear Teabiscuit is the following post you posted 5th December 2018

''this is disappointing reaction on the market given that this is the best RNS Farn has released for some time. Aim as usual and the mm always dictate everything... This to be fair should at minimum have recovered over a pound.''

Your post not mine!

GL




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.